KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Equivalents (2016 - 2026)

Gsk has reported Cash & Equivalents over the past 18 years, most recently at $4.6 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 17.47% year-over-year to $4.6 billion; the TTM value through Mar 2026 reached $4.6 billion, down 17.47%, while the annual FY2025 figure was $4.5 billion, 9.03% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $4.6 billion at Gsk, up from $4.5 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $14.7 billion in Q1 2022 and troughed at $3.5 billion in Q1 2023.
  • A 5-year average of $5.1 billion and a median of $4.4 billion in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 124.34% in 2022 and later tumbled 76.13% in 2023.
  • Year by year, Cash & Equivalents stood at $4.4 billion in 2022, then dropped by 16.55% to $3.6 billion in 2023, then skyrocketed by 36.31% to $5.0 billion in 2024, then decreased by 9.03% to $4.5 billion in 2025, then increased by 2.7% to $4.6 billion in 2026.
  • Business Quant data shows Cash & Equivalents for GSK at $4.6 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.4 billion in Q3 2025.